Innate Pharma S.A. (IPH.PA)

3,2640 +0,0540 (+1,68 %) À la clôture : 05:35PM CET

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 213

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Mondher Mahjoubi M.D.	Chairman of Exec. Board & CEO	1,05M	S.O.	1958
Mr. Yannis Morel Ph.D.	Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board	415,85k	S.O.	1973
Dr. Herve Brailly	Co-Founder & Chairman of Supervisory Board	S.O.	S.O.	1961
Dr. François Romagné Ph.D.	Founder	S.O.	S.O.	1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Sr. VP & Chief Scientific Officer	S.O.	S.O.	1964
Dr. Marc Bonneville Ph.D.	Founder	S.O.	S.O.	1960
Mr. Jean Jacques Fournié Ph.D.	Founder	S.O.	S.O.	S.O.
Mr. Alessandro Moretta M.D., Ph.D.	Founder	S.O.	S.O.	S.O.
Mr. Frederic Lombard M.B.A.	Sr. VP & CFO	S.O.	S.O.	1975
Ms. Odile Belzunce	VP of Compliance & Operations	S.O.	S.O.	1980

Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Innate Pharma S.A. en date du 1 février 2023 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 1; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.